What is the recommended treatment for anterior uveitis?

Treatment of Anterior Uveitis

For acute noninfectious anterior uveitis, topical corticosteroids—specifically prednisolone acetate 1%—are the first-line treatment, with ophthalmology referral and coordination essential for optimal outcomes. 1, 2, 3, 4

Initial Management Algorithm

First-Line Therapy

• Start topical prednisolone acetate 1% eyedrops as the primary treatment for active anterior uveitis 1, 2, 5, 3, 4
• Initial dosing frequency varies in practice, with 6 times daily while awake being most common among specialists, though some use higher frequencies initially 4
• Add cycloplegic agents (e.g., cyclopentolate, atropine) to prevent posterior synechiae formation and reduce ciliary spasm pain 1, 2
• Arrange ophthalmology follow-up within 1 week for initial cases 1

Critical Caveat

Do not start corticosteroids before ophthalmologic examination if infection (particularly herpetic keratitis/uveitis) is suspected, as steroids can worsen infectious conditions and mask accurate diagnosis 1

Escalation Strategy Based on Response

If Inadequate Response at 2-3 Weeks

When inflammation persists despite initial topical therapy:

• Switch to difluprednate eyedrops (stronger topical steroid) - chosen by 41.2% of specialists 4
• Alternative: Add oral prednisone systemically - chosen by 28.4% of specialists 4
• Coordinate treatment decisions with ophthalmologist 1

Threshold for Systemic Immunosuppression

Add systemic therapy if:

• Patient requires ≥1-2 drops/day of prednisolone acetate 1% for ≥3 months to maintain control 6, 5
• Poor prognostic factors present at first visit (posterior synechiae, elevated intraocular pressure, cystoid macular edema) 6, 2
• Recurrent episodes despite topical therapy 2, 7
• Development of corticosteroid-related complications (glaucoma, cataracts) 6, 5

Goal: Discontinue topical corticosteroids due to risk of glaucoma and cataracts 6, 5

Systemic Immunosuppression Protocol

First-Line Systemic Agent

• Methotrexate is the first choice for systemic immunosuppression 6, 2, 5
• Subcutaneous methotrexate is preferred over oral administration for better efficacy, though this is a conditional recommendation 5
• Methotrexate achieved remission in 52.1% (95% CI, 38.6%-67.1%) of posterior uveitis patients, with similar efficacy expected for anterior disease requiring systemic therapy 3

Second-Line Systemic Options

If methotrexate fails or is not tolerated:

• Switch to or add monoclonal antibody TNF inhibitors (adalimumab or infliximab) 6, 2, 5, 3
• Adalimumab extended time to treatment failure to 24 weeks vs 13 weeks with placebo and reduced treatment failure from 78.5% to 54.5% 3
• Do NOT use etanercept for uveitis—it is ineffective and conditionally recommended against 6, 2, 5

Alternative DMARDs

• Mycophenolate mofetil controlled inflammation in 70.9% (95% CI, 57.1%-83.5%) of cases 3
• Other options include leflunomide, cyclosporine, azathioprine 2, 5, 7

Special Considerations

Severe Active Disease with Sight-Threatening Complications

Start methotrexate AND monoclonal antibody TNF inhibitor immediately (combination therapy from onset) rather than methotrexate monotherapy 5

• Severe disease includes: ocular structural complications, macular edema, optic nerve involvement, or complications from topical steroid therapy 5

JIA-Associated Anterior Uveitis

• Same topical corticosteroid approach initially 6, 2, 5
• Lower threshold for systemic therapy due to chronic nature 6, 2, 5
• Requires regular screening every 3 months in high-risk patients (ANA positive, age <7 years, disease duration <4 years) 6, 5

Immune Checkpoint Inhibitor-Related Uveitis

For grade 2 anterior uveitis in cancer patients on immunotherapy:

• Hold immune checkpoint inhibitor 1
• Urgent ophthalmology referral within 2 days before starting treatment 1
• Coordinate topical corticosteroids and cycloplegics with ophthalmologist 1

Monitoring During Treatment

Active Disease on Topical Therapy

• Follow-up within 1 week for initial presentation 4
• More frequent monitoring (every 1-2 weeks) during active tapering 6, 5

Controlled Disease

• Ophthalmologic monitoring at least every 3 months when on stable therapy 6, 5
• Within 1 month after each change in topical glucocorticoids 6, 5
• Within 2 months after changing systemic therapy 6, 5

Duration Before Reducing Systemic Therapy

Recommend 2 years of inactive disease off topical steroids before reducing systemic immunosuppression 2

Common Pitfalls to Avoid

• Never delay ophthalmology referral—anterior uveitis can progress to posterior involvement, which may be asymptomatic but lead to vision loss 1
• Do not continue topical steroids >3 months as monotherapy if inflammation persists—this increases risk of glaucoma and cataracts without addressing underlying disease 6, 5
• Avoid etanercept for uveitis treatment despite its efficacy for arthritis—it is ineffective and potentially harmful for ocular inflammation 6, 2, 5
• Early initiation of immunomodulation (within first few months) is associated with lower risk of glaucoma and better visual outcomes at 2 years 8
• Rule out infectious causes (toxoplasmosis, herpes, tuberculosis, HIV) before starting immunosuppression, as these comprise 11-21% of cases in high-income countries 3